Search
forLearn
5 / 801 resultslearn 2-deoxy-D-Ribose
learn ceramide 2
learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
learn ORPL
Research
5 / 102 results
research Simultaneous determination of multi-class active pharmaceutical ingredients by UHPLC-HRMS
A new method was developed to accurately detect and measure 47 different drug ingredients in various products.
research Isolation and Structural Characterization of Degradation Products of Finasteride by Preparative HPLC, HRMS and 2D NMR
Finasteride forms three new products under acidic stress.
research Determination of adulteration in hair serums by LC-HRMS §
A new method found unlisted drugs in two popular hair serums, posing a health risk.
research UHPLC-Q-Orbitrap HRMS-based Metabolomics and In Silico Studies on 5-α-Reductase, JAK1, JAK2, and JAK3 of Albizia saponaria L.: Application to Alopecia
Albizia saponaria bark extract may help treat hair loss.
research Isolation and Structural Characterization of Finasteride Degradation Products by Preparative HPLC, HRMS, and NMR
This study investigates the degradation profile of finasteride, a drug used for benign prostatic hyperplasia and androgenetic alopecia, under stress conditions. Using LC–MS, three degradation products were identified under acidic conditions, with minimal degradation in alkaline and oxidative environments. The degradation products were isolated and analyzed using preparative HPLC, HRMS, and NMR spectroscopy. The study revealed that the degradation process of DP-1 involved cleavage of the tert-butyl amide and addition of water across the alkene moiety. The structure of DP-1 was established through various spectroscopic techniques, and it, along with other degradation products, was found to be previously undescribed. These findings enhance the understanding of finasteride's degradation chemistry, aiding impurity profiling, stability studies, and quality control of its formulations.
Community Join
5 / 1000+ resultscommunity Since there is so much hype for cosmeRNA and HMI-115...
Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.
community HMI 115 Phase 1 update: Changes to clinicaltrials.gov page
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.
community What's going on with hmi115? The Phase 2 was concluded Nov2024 but no news
Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.
community HMI 115 hasn't done phase one yet for AGA?
User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.
community HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.